Surfaxin

(Lucinactant)

Phase 3Small molecule

LLees Hk

Surfaxin is one of 72 small molecule programs targeting Bronchopulmonary Dysplasia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Bronchopulmonary DysplasiaActive, not recruiting

Respiratory FailureActive, not recruiting

COVID-19Active, not recruiting

Meconium Aspiration SyndromeActive, not recruiting

Bronchopulmonary DysplasiaPhase 2

Active, not recruiting

Respiratory FailurePhase 2

Active, not recruiting

COVID-19Phase 2

Active, not recruiting

Meconium Aspiration SyndromePhase 3

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Surfaxin

LLees Hk

Phase 3

1 2

Calciferol

Alnylam Pharmaceuticals

Preclinical

—3

Aquasol E

NNational Eye Institute (NEI)

Preclinical

1 4

Tricor

JJagotec

Preclinical

1 5

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 6

Statin

Bristol-Myers Squibb

Preclinical

1 7

Selenium

SSWOG Cancer Research Network

Preclinical

1 8

Vit D

PPost Graduate Institute of Medical Education and Research, Chandigarh

Preclinical

1 9

Tpa

UUniversity of Florida

Preclinical

1 10

Other Tkis

Bayer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

COVID-191 trial

The Safety and Preliminary Tolerability of Lyophilized Lucinactant in Adults With Coronavirus Disease 2019 (COVID-19)

Completed·WWindtree Therapeutics·Phase 2·NCT04389671·20 enrolled

Respiratory Failure1 trial

Lucinactant for Treatment of Acute Hypoxemic Respiratory Failure in Children up to Two Years Old

Completed·WWindtree Therapeutics·Phase 2·NCT00578734·165 enrolled

Safety and Efficacy1 trial

The Safety and Efficacy of Lucinactant for Inhalation in Premature Neonates 26 to 32 Weeks Gestational Age

Completed·WWindtree Therapeutics·Phase 2·NCT02636868·221 enrolled

Bronchopulmonary Dysplasia1 trial

SURFAXIN® Treatment for Prevention of Bronchopulmonary Dysplasia (BPD) in Very Low Birth Weight (VLBW) Infants.

Terminated·WWindtree Therapeutics·Phase 2·NCT00215540·136 enrolled

Trial1 trial

Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates

Completed·WWindtree Therapeutics·Phase 2·NCT02074059·80 enrolled

1 more indication

Meconium Aspiration Syndrome1 trial

Phase III Randomized Study of Lucinactant in Full Term Newborn Infants With Meconium Aspiration Syndrome

Terminated·WWindtree Therapeutics·Phase 3·NCT00004500·69 enrolled

Regulatory

FDA Approval Timeline[4]

Mar 6, 2012

SURFAXIN

NDA NDA021746

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Lucinactant. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lucinactant compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lucinactant. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA021746). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Lees Hk company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: LLees Hk

Surfaxin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

COVID-191 trial

Respiratory Failure1 trial

Safety and Efficacy1 trial

Bronchopulmonary Dysplasia1 trial

Trial1 trial

Meconium Aspiration Syndrome1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News